Up to date Nov. 13, 2023 6:50 pm ET
The Meals and Drug Administration could quickly approve two gene therapies with the potential to treatment greater than 100,000 Individuals with debilitating sickle-cell illness. Now the dangerous information: The Facilities for Medicare and Medicaid Providers (CMS) could quickly restrict entry to such breakthrough remedies.
Gene therapies repair lacking or faulty genes. The one-time remedies have the potential to treatment inherited problems with early demise sentences. The FDA has authorized 9 gene therapies for such illnesses as Duchenne muscular dystrophy, spinal muscular atrophy and retinal dystrophy.
Copyright ©2023 Dow Jones & Firm, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8